Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation

Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible lung disease with high mortality rate. The etiology is unknown and treatment choices are limited. Thus, there is great interest to investigate novel agents for IPF therapy. Ibrutinib, BTK, and ITK irreversible inhibitor is a FDA-a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Inflammation 2018-06, Vol.41 (3), p.904-913
Hauptverfasser:	Gu, Yangyang, Huang, Bo, Yang, Yanfei, Qi, Mengdie, Lu, Guohua, Xia, Dajing, Li, Hequan
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Apoptosis B-cell lymphoma Biomedical and Life Sciences Biomedicine Bleomycin Bleomycin - adverse effects Disease Models, Animal Epithelial cells Epithelial Cells - pathology Etiology Extracellular matrix Fibrosis Humans Idiopathic Pulmonary Fibrosis - etiology Immunology Inflammation - chemically induced Inhibitor drugs Internal Medicine Itk protein Lung diseases Lymphocytes B Mice Original Article Pathology Pharmacology/Toxicology Pulmonary fibrosis Pulmonary Fibrosis - chemically induced Pyrazoles - pharmacology Pyrimidines - pharmacology Rheumatology Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!